Pliant Therapeutics

Historical price data

Pliant Therapeutics is pioneering a new approach to treating fibrotic diseases by targeting the biological pathways that drive fibrosis, specifically through integrin-mediated activation of TGF-β. The company's most advanced program, bexotegrast, has demonstrated promising safety and efficacy signals in mid-stage clinical trials for IPF and PSC, positioning it as a potential first-in-class oral therapy. With a robust pipeline of integrin-targeted candidates and a strong intellectual property position, Pliant aims to address the substantial market opportunity in fibrotic diseases, which currently lack effective anti-fibrotic treatments.

A platform focused on developing small molecule and antibody inhibitors of specific integrins (αvβ1, αvβ6, αvβ8) to selectively block the localized activation of TGF-β, a central mediator of fibrosis and immune suppression in the tumor microenvironment.

8 drugs in pipeline

In IPF, Pliant competes with approved therapies Ofev and Esbriet, and mid-stage assets from larger pharma like BMS. Its key differentiation is a novel integrin-targeting mechanism aimed at the root cause of fibrosis. In PSC, it aims to be a first-to-market therapy, facing less late-stage competition.